Refilings and Errors List
On October 25, 2002, we introduced the Refilings and Errors List (the List) on the Commission's web site. The purpose of the List is to provide transparency to the market when, during a staff review, an issuer has amended its CD record, website or social media.
The List identifies issuers and investment funds with deficiencies identified during a staff review and that leads to Corrective Disclosure and will result in the issuer or investment fund being placed on the List. Please note that we will add the name of an issuer or investment fund to the List irrespective of whether the deficiency was identified by staff, by the issuer or investment fund or their advisors during the review process. We will also add the issuer or investment fund to the List regardless of whether the Commission ordered the filing or refiling, or the issuer or investment fund took this step voluntarily.
An issuer or investment fund’s name will be kept on the List for a period of three years from the date the Corrective Disclosure is made to the Continuous Disclosure record or website, or on social media. After the three-year period, the issuer or investment fund’s name will be archived.
For additional information and examples regarding Corrective Disclosure, please refer to OSC Staff Notice 51-711 (Revised) Refilings and Corrections of Errors
Reasons for Refilings: The Company amended and refiled its March 31, 2022 and December 31, 2021 Management Discussion and Analysis (“MD&A”) to enhance disclosure relating to, among other things, COVID-19 impacts, current projects of the Company and their status, overall performance, and discussions of operations, including its SponsorCoin Platform and the Hemp products and Vitamin Shots marketplace and the Ready to Drink (“RTD”) spirits and premium spirits, transactions between related parties, and liquidity and cash resources. The Company has also enhanced its disclosure regarding the regulatory framework relating to regulated Hemp and Alcohol products in each jurisdiction where the Company operates. The Company also filed a material change report regarding the appointment of Charles Sung as the CFO on March 9, 2022.
The Issuer refiled its financial statements and MD&A for the interim period ended June 30, 2022 to correct the Statements of Cash Flows, which (1) erroneously referred to the current and comparative periods disclosed as “December 31, 2022 and 2021” instead of “June 30, 2022 and 2021”; and (2) presented the incorrect financial information for the comparative period. The Q2 2022 MD&A was also revised to correct commentary related to the Statements of Cash Flows, reflecting changes to the financial information for the 2021 comparative period presented in the revised Q2 2022 financial statements, and an erroneous reference to “the three months ended March 31, 2022”, which should refer to the “the six months ended June 30, 2022”
AIF and Technical Report did not comply with NI 43-101 (deficiency 2
The management reports of fund performance for the annual period ended December 31, 2014 and interim period ended June 30, 2015 were restated to correct the trading expense ratio for the periods ended December 31, 2014 and June 30, 2015.